Active, not recruitingPhase 2NCT05402345
A Study of GlcNAc on Tear Production in NGLY1-CDDG
Studying Alacrimia-choreoathetosis-liver dysfunction syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eva Morava-Kozicz
- Principal Investigator
- Eva Morava-Kozicz, MD, PhD, M.DIcahn School of Medicine at Mount Sinai
- Intervention
- GlcNAc-GlcN(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 1-60 years · All sexes
- Timeline
- 2025 – 2026
Study locations (2)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital, Seattle, Washington, United States
Collaborators
Children's Hospital of Philadelphia · Seattle Children's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05402345 on ClinicalTrials.govOther trials for Alacrimia-choreoathetosis-liver dysfunction syndrome
Additional recruiting or active studies for the same condition.
See all trials for Alacrimia-choreoathetosis-liver dysfunction syndrome →